BiVictriX Therapeutics Plc (LON:BVX – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 7.13 ($0.09) and last traded at GBX 9 ($0.11), with a volume of 1534525 shares. The stock had previously closed at GBX 8.25 ($0.11).
BiVictriX Therapeutics Stock Performance
The company has a quick ratio of 7.49, a current ratio of 6.85 and a debt-to-equity ratio of 14.51. The business has a fifty day simple moving average of GBX 12.32 and a 200-day simple moving average of GBX 11.72. The firm has a market cap of £8.25 million, a P/E ratio of -250.00 and a beta of -0.61.
About BiVictriX Therapeutics
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
Further Reading
- Five stocks we like better than BiVictriX Therapeutics
- What Investors Need to Know to Beat the Market
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Jeff Brown’s Exegesis AI Stock Picks
- What Does Downgrade Mean in Investing?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for BiVictriX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiVictriX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
